Back to results
US 2024/0402191 A1Published application
Ivaltinostat combination therapy for treating pancreatic cancer
AssigneeCG Pharmaceuticals, Inc
InventorsSangsook Cho, Joong Myung Cho
Life of this patent
Estimating the term…
Abstract
Embodiments of the present disclosure relates to ivaltinostat combination therapy for treating pancreatic cancer in subjects having low levels of serological protein biomarkers with negative correlation to progression-free survival (PFS).
Claims37
A method of providing pancreatic cancer treatment to a subject in need thereof, comprising:
- receiving information on a baseline expression level of one or more serological protein biomarkers selected from the group consisting of TIMP1, pro-MMP10, and PECAM1 (CD31) in the subject prior to the treatment;
- administering an effective amount of ivaltinostat in combination with one or more additional anti-cancer agents to the subject;
- and
- determining the subject's response to the pancreatic cancer treatment.
1 more element
A method of treating pancreatic cancer in a subject in need thereof, comprising:
- receiving information on a subject's serological protein biomarker TIMP1 expression level prior to the treatment;
- selecting the subject with a TIMP1 expression level of about 200 ng/ml or less;
- and
- administering an effective amount of ivaltinostat in combination with one or more additional anti-cancer agents to the subject.
1 more element
A method of treating pancreatic cancer in a subject in need thereof, comprising:
- receiving information on a subject's serological protein biomarker pro-MMP10 expression level prior to the treatment;
- selecting the subject with a pro-MMP10 expression level of about 500 pg/mL or less;
- and
- administering an effective amount of ivaltinostat in combination with one or more additional anti-cancer agents to the subject.
1 more element
A method of treating pancreatic cancer in a subject in need thereof, comprising:
- receiving information on a subject's serological protein biomarker PECAM1 (CD31) expression level prior to the treatment;
- selecting the subject with a PECAM1 expression level of about 7.5 ng/ml or less;
- and
- administering an effective amount of ivaltinostat in combination with one or more additional anti-cancer agents to the subject.
1 more element
(canceled)
Dependencies are inferred from the claim text.